Spots Global Cancer Trial Database for Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
Official Title: A Phase I Open-Label Study to Assess the Safety, Tolerability and PK of Ascending Multiple Oral Doses of AZD2171 When co-Administered With Fixed Multiple Oral Doses of ZD1839 (250mg or 500mg Once Daily) in Patients With Advanced Cancer
Study ID: NCT00502060
Conditions
Study Description
Brief Summary: Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Amsterdam, , Netherlands
Research Site, Nijmegen, , Netherlands
Research Site, Utrecht, , Netherlands
Contact Details
Name: Nick Botwood, BSc, MBBS, MRCP, MFPM
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: G Giaccone, Prof
Affiliation: Vrije Universiteit Medical Centre
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
